Rifaximin Improves Insulin Resistance in Metabolic Syndrome and Reduces Insulin Requirement in Type 2 Diabetes
试验速览
- 阶段
- 不适用
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- change in glycemic control
研究概览
简要总结
Gut Dysbiosis had been involved in some way in the pathogenesis of some extra-intestinal disorders including metabolic syndrome, cardiovascular disease, and obesity.
详细描述
Accumulating evidence had linked metabolic syndrome and diabetes to dysequilibrium in gut microbiota, which are a critical regulator of host metabolism and immune responses. gut microbiota interacts with host signaling pathways, leading to modulation of the endocrine system, immune responses. gut microbial metabolites, in particular, short-chain fatty acids, have been significantly associated with liability to diabetes. patients with positive fecal short-chain fatty acids will be given rifaximin
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diabetes with gut dysbiosis
排除标准
- •recent antibiotic use
- •pregnancy
- •diabetogenic drugs
研究组 & 干预措施
study
干预措施: Rifaximin 200 MG (Drug)
结局指标
主要结局
change in glycemic control
时间窗: 3 months
Fasting blood sugar, post-prandial blood sugar (mg/dl)
次要结局
- Gastrointestinal symptom questionnaire(1 month)
研究者
Amr Shaaban Hanafy
Assistant professor of medicine
Zagazig University